Loss of low-density lipoprotein utilization by regressing porcine luteal cells: effects of protein kinase C activation.
We recently reported a decline in low-density lipoprotein (LDL) uptake by regressing porcine luteal cells that correlated with diminished LDL stimulation of progesterone (P) production. The objectives of the present study were to determine 1) whether loss of LDL utilization is a specific lesion in the steroidogenic pathway in regressing luteal cells and 2) whether in vitro activation of protein kinase C (PKC) in mid-cycle luteal cells acutely suppresses LDL utilization. Dispersed cells (4 x 10(4)/0.2 ml) from mid-(Days 6-10, estrus = Day 0; n = 5) or late-(Days 15-18; n = 7) cycle porcine CL were cultured in Dulbecco's Modified Eagle/F-12 medium supplemented with insulin, transferrin, sodium selenite, and aprotinin for 24 h with human (h) LDL (0-100 micrograms/ml), 22(R)-hydroxycholesterol (22[OH]-C;-0-25 micrograms/ml), or pregnenolone (0-1000 nM). P production by mid-cycle luteal cells was dose-dependently increased (p < 0.05) by LDL (up to 2.8-fold), 22(OH)-C (up to 3.2-fold), and pregnenolone (> 3-fold). In contrast, LDL (10-100 micrograms/ml) failed to stimulate P production by late-cycle luteal cells. But 22(OH)-C (up to 4-fold) and pregnenolone (> 10-fold) were as effective in promoting (p < 0.05) steroidogenesis relative to basal levels in late luteal cells as in mid-cycle cultures. The PKC activator, TPA (12-O-tetradecanoyl-phorbol-13-acetate; 10 ng/ml), inhibited (approximately 20%; p < 0.01) basal and LDL-supported steroidogenesis, but did not suppress 22(OH)-C-stimulated P secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
Brannian
J D
JD
Department of Obstetrics and Gynecology, University of South Dakota School of Medicine, Sioux Falls 57105-1570, USA.
Christianson
H
H
Flynn
S
S
Kurz
S G
SG
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D003338:Corpus Luteum / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D004971:Estrus; D005260:Female; D006888:Hydroxycholesterols / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000378:metabolism* / Q000494:pharmacology; D003341:Luteolysis; D011284:Pregnenolone / Q000494:pharmacology; D011374:Progesterone / Q000096:biosynthesis; D011493:Protein Kinase C / Q000378:metabolism*; D018038:Sodium Selenite / Q000494:pharmacology; D013552:Swine; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014168:Transferrin / Q000494:pharmacology
D006888:Hydroxycholesterols; D007328:Insulin; D008077:Lipoproteins, LDL; D014168:Transferrin; C003585:22-hydroxycholesterol; D011374:Progesterone; D011284:Pregnenolone; D007611:Aprotinin; D011493:Protein Kinase C; D018038:Sodium Selenite; D013755:Tetradecanoylphorbol Acetate